

Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service



ADULT MEDICATION GUIDELINE						
Sugammadex						
Scope (Staff):	All WNHS Staff					
Scope (Area):	Obstetrics and Gynaecology					
This document should be read in conjunction with the Disclaimer.						

Quick Links									
Dose	Administration	Monitoring	Pregnancy and Breastfeeding						
Restrictions									
Formulary: Restricted									
Medication Class									
Detoxifying agent, antidote									
Presentation									
Vial: 200mg/2mL, 500mg/5mL									
Storage	Storage								
Store below 30°C. Do not freeze. Protect from light.									
Dose									
Reversal of neuromuscular blockade:									
Emergency situations	Emergency situations (immediate reversal):								
IV: 16mg/kg									
Doop rovorsal:									
Deep reversal: IV: 4mg/kg									
Standard reversal:									
IV: 2mg/kg									

# Administration

Refer to the Australian Injectable Drugs Handbook

### Monitoring

#### Intra-operative monitoring; record:

- Neuromuscular blockade used (rocuronium or vecuronium)
- Monitoring method and results prior to sugammadex administration
- Time (sec) to TOFR > 70% / no fade on DBS after sugammadex is administered (optional)

#### Post-operative monitoring; record (on arrival at PACU and after 15 and 30 minutes):

- Airway type
- O<sub>2</sub> delivery type
- O<sub>2</sub> flow rate (L/min)
- Respiratory rate
- SaO<sub>2</sub>
- Sedation score
- Temperature

### Pregnancy

1<sup>st</sup> Trimester: Considered safe to use

2<sup>nd</sup> Trimester: Considered safe to use

3<sup>rd</sup> Trimester: Considered safe to use

### **Breastfeeding**

Considered safe to use

#### Comments

Sugammadex can reduce the amount of progesterone available from hormonal contraceptives. For oral contraceptives, any dose taken on the same day as sugammadex is considered as a missed dose. For other hormonal contraceptive methods (i.e. IUD, implant, depot) use other forms of contraception for 7 days.

## **Related Policies, Procedures & Guidelines**

Pre-operative Medication Management

WATAG Sugammadex (Bridion®) – Guidelines for use

#### References

NPS Medicine Wise. Sugammadex.NPS Australian Prescriber 2009; 32:82-6. Available:

https://www.nps.org.au/australian-prescriber/articles/sugammadex

William R, Bryant H. Sugammadex advice for women of childbearing age. Anaesthesia:Vol 73(1):133-4. Available: <u>Sugammadex advice for women of childbearing age - Williams - 2018 - Anaesthesia - Wiley Online Library</u>

Australian Medicines Handbook. Sugammadex. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 [cited 2021 Jun 18]. Available from: https://amhonline.amh.net.au/

The Royal Women's Hospital. Sugammadex. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Jun 18]. Available from: https://thewomenspbmg.org.au/

Society of Hospital Pharmacists of Australia. Sugammadex. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 [cited 2021 Jun 18]. Available from: http://aidh.hcn.com.au

Western Australian Therapeutic Advisory Group (WATAG). Sugammadex Guidelines. WATAG Guidelines [Internet]. 2016 [updated 2013 July; cited 2021 Jul 8].

Keywords	Sugammadex, Bridion, neuromuscular blockade, reversal							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH Pharmacy Department							
Version Info:	4.0							
Date First Issued:	05/2015	Last Reviewed:	08/07/2021		Review Date:	08/07/2024		
Endorsed by:	Medicines and Therapeutics Committee				Date:	16/09/2021		
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety				
	Std 3: Preventing and Controlling Healthcare Associated Infection			Std 7: Blood Management				
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration				
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.								

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.